Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Semaglutide shows promise in NASH phase 2 study

Publish date:: November 13, 2020

Key clinical point: Higher nonalcoholic steatohepatitis resolution levels were seen than had been previously demonstrated.

Major finding: At highest dose, 59% had nonalcoholic steatohepatitis resolution, and no fibrosis worsening.

Study details: A randomized, placebo-controlled trial with 320 subjects.

Disclosures: The study was sponsored by Novo Nordisk. Dr. Newsome reported disclosures related to Novo Nordisk during the conduct of the study, and to Pharmaxis, Boehringer Ingelheim, Echosens, Bristol-Myers Squibb, Gilead, Pfizer, and Poxel. Several of the other study authors reported receiving fees and grants from various pharmaceutical companies, including Novo Nordisk. One author reported pending patents for the use of semaglutide.

Citation:

Newsome PN et al. N Engl J Med. 2020 Nov 13. doi: 10.1056/NEJMoa2028395.

This Week's Must Reads

Higher dose maximizes effects of magnesium sulfate for obese women,

Microplastics permeate human placentas,

One in five gestational carriers do not meet ASRM criteria,

Gender surgical outcomes differ following puberty suppression,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Must Reads in Diabetes

Sac/val heart failure benefit extends to diabetes patients,

Don’t miss cardiovascular risk factors in transgender patients,

Semaglutide shows promise in NASH phase 2 study,

‘Modest’ benefit for post-MI T2D glucose monitoring,

Diabetic neuropathic pain linked to brain bioenergic anomalies,